Key result
In a rat model of ischemic heart failure, losartan significantly attenuated the increase in left atrial diameter compared to the heart failure control group (P=0.028) and reduced atrial fibrosis.
Why the study?
Does losartan prevent structural atrial remodeling in a rat model of ischemic heart failure?
Does losartan prevent structural atrial remodeling in a rat model of ischemic heart failure?
Absolute Event Rate: 7.3% vs 8.5%
p-value: p=0.028
In a rat model of ischemic heart failure, the ARB losartan attenuated left atrial enlargement and fibrosis but did not significantly reduce atrial fibrillation inducibility.
Losartan may limit atrial remodeling in experimental ischemic HF; hypothesis-generating for human AF prevention trials.
The remodeling of gap junctions may affect their conduction properties and contribute to the maintenance of atrial fibrillation. The significance of the role of angiotensin-II receptor blockers (ARBs) in upstream therapy is not clear. This study was performed to investigate the effects of ARBs on atrial remodeling in a heart failure model. A model of heart failure was established or sham surgery performed in 24 Sprague-Dawley male rats. The rats were divided into sham, heart failure and heart failure-ARB groups. In the ARB group, 30 mg/kg of losartan was administered each day for 4 weeks. Echocardiography was performed at the baseline and 4 weeks following the surgery. An atrial fibrillation induction study and histological and immunohistochemical evaluation were performed 4 weeks after surgery. The increase in the left atrial diameter of the heart failure-ARB group was smaller than that of the heart failure group (P=0.028). The atrial fibrillation inducibility and duration of induced atrial fibrillation were not different between the heart failure and heart failure-ARB groups. Masson's trichrome staining revealed less fibrosis in the heart failure-ARB group compared with the heart failure group. Immunohistochemical staining and western blot analysis for connexin 43 showed a lower expression level in the heart failure-ARB group compared with that in the heart failure group. In a rat model of ischemic heart failure the ARB losartan had structural and histological atrial reverse-remodeling effects. However, its role as an electrical stabilizer requires further study.
No takes yet. Share an insight, caveat, or question.
Yoon et al. (2013) studied Ischemic heart failure (n=24). Losartan vs. Heart failure (no ARB) and sham was evaluated on Increase in left atrial diameter (LAD) (p=0.028). In a rat model of ischemic heart failure, losartan significantly attenuated the increase in left atrial diameter compared to the heart failure control group (P=0.028) and reduced atrial fibrosis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: